Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.

Détails

ID Serval
serval:BIB_467B24623EBB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Périodique
Future oncology
Auteur(s)
Goebell P.J., Ivanyi P., Bedke J., Bergmann L., Berthold D., Boegemann M., Busch J., Doehn C., Krege S., Retz M., Amsberg G.V., Grimm M.O., Gruenwald V.
ISSN
1744-8301 (Electronic)
ISSN-L
1479-6694
Statut éditorial
Publié
Date de publication
10/2020
Peer-reviewed
Oui
Volume
16
Numéro
29
Pages
2307-2328
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
The therapy of advanced (clear-cell) renal cell carcinoma (RCC) has recently experienced tremendous changes. Several new treatments have been developed, with PD-1 immune-checkpoint inhibition being the backbone of therapy. Diverse immunotherapy combinations change current first-line standards. These changes also require new approaches in subsequent lines of therapy. In an expert panel, we discussed the new treatment options and how they change clinical practice. While first-line immunotherapies introduce a new level of response rates, data on second-line therapies remains poor. This scenario poses a challenge for clinicians as guideline recommendations are based on historical patient cohorts and agents may lack the appropriate label for their in guidelines recommended use. Here, we summarize relevant clinical data and consider appropriate treatment strategies.
Mots-clé
RCC, TKI, VEGFR inhibitor, advanced (clear-cell) renal cell carcinoma, checkpoint inhibition, mTOR inhibitor, tyrosine kinase inhibitor
Pubmed
Web of science
Open Access
Oui
Création de la notice
26/09/2020 15:09
Dernière modification de la notice
08/12/2020 6:24
Données d'usage